Fibromyalgia is most often associated with chronic pain, but the condition rarely stops there. Symptoms like fatigue, poor sleep, tenderness, and fibro fog can also have a major impact on daily life. Cortisol helps regulate inflammation and stress response, both of which can influence how fibromyalgia symptoms persist over time.
Cortisol also helps the body control the four clinical manifestations of inflammation: heat, redness, swelling, and pain. When cortisol is in balance, it helps bring that inflammatory response back under control. When it’s out of balance, inflammation can last longer than it should, creating the perfect storm for ongoing symptoms and flare-ups.
When Cortisol Falls Out of Balance
Helen Foundation founder Dr. Virgil Stenberg developed Microdose Therapy™ around a foundational principle: the body normally produces an emergency cortisol pulse in response to stress and inflammation. When that pulse is weak, delayed, or missing, inflammation may persist, allowing symptoms to continue instead of calming down.
Microdose Therapy™ helps support the body’s natural response through patient self-administration of cortisol under the safe use limit, helping patients pursue meaningful, sustained symptom relief.
The program uses hydrocortisone, daily symptom tracking, patient education, physician oversight, and guided support to help patients understand baseline symptoms, recognize flare-ups earlier, and respond more consistently over time. Patients use Relief Radar, an online portal, to record symptom severity, medication use, and overall progress, creating a clearer picture of how symptoms change and how much—or how little—support may be needed.
Microdose Therapy™ also differs from standard low-dose steroid use by focusing on very small amounts and careful self-administration. Daily average daily use is generally 3 mg, far below the roughly 25 mg of cortisol the body normally produces each day.¹
The Science Behind Microdose Therapy™
A 1990 animal study found that inflammation itself triggered the release of adrenocorticosteroid hormones, which then acted as a feedback mechanism to suppress the inflammatory response. The finding supports the idea that cortisol is part of the body’s normal system for bringing inflammation back under control.²
Subsequent clinical research supported the same conclusion. In a 1992 double-blind, crossover clinical trial involving patients with rheumatoid arthritis, prednisone therapy produced additional reductions from baseline in both tender joint count and total pain score, while adverse events were no more frequent than with placebo. Although that study focused on rheumatoid arthritis rather than fibromyalgia, it added important real-world supporting the idea that carefully managed corticosteroid therapy could reduce inflammatory symptoms safely and effectively.³
Fibromyalgia-specific findings followed. In a 2019 Journal of Inflammation Research study, patients using this model showed an average 77% symptom improvement for fibromyalgia. The same study also reported improvement in rheumatoid arthritis, multiple sclerosis, and asthma, along with no significant adverse reactions among the 2,015 patients who completed treatment.⁴
A More Informed Path to Relief
For people living with fibromyalgia, relief is about more than lowering pain for a day or two. Better sleep, clearer thinking, improved energy, and fewer interruptions from flare-ups can all make a meaningful difference.
Microdose Therapy™ was designed to support relief through a more structured, patient-guided process rooted in symptom tracking, education, and ongoing support. By helping patients recognize changes earlier and respond more consistently over time, the program offers a more informed way to manage fibromyalgia symptoms and regain a greater sense of control in daily life.
If you’re ready to learn more about how Microdose Therapy™ may help relieve fibromyalgia symptoms, connect with us today.
Sources
- Stenberg, Virgil I. Arthritis: The Simple Solution. Grand Forks, ND: Zahn Pub., 2000.
- Stenberg, V.I., Bouley, M.G., Katz, B.M. et al. Negative endocrine control system for inflammation in rats. Agents and Actions 29, 189–195 (1990). https://doi.org/10.1007/BF01966446
- Stenberg VI, Fiechtner JJ, Rice JR, Miller DR, Johnson LK. Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial. International Journal of Clinical Pharmacology Research. 1992 ;12(1):11-18. PMID: 1526694. https://europepmc.org/article/med/1526694
- Irwin JB, Baldwin AL, Stenberg VI. General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity. J Inflamm Res. 2019;12:161-166 https://doi.org/10.2147/JIR.S195165